Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China
机构：[1]Eye & ENT Hospital, Shanghai Medical College, Fudan University, FenyangRoad 83, Shanghai, Xuhui District 200031, China[2]Department ofOphthalmology, the Fourth People’s Hospital of Shenyang, Shenyang, China[3]Department of Ophthalmology, the People’s Hospital of Jiangsu, Nanjing, China[4]Eye Center of the 2nd Affiliated Hospital, Medical College of ZhejiangUniversity, Hangzhou, China[5]Shanxi Eye Hospital, Taiyuan, China[6]BeijingInstitute of Ophthalmology, Beijing Tongren Hospital, Capital University ofMedical Science, Beijing, China研究所眼科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院[7]Eye Hospital, Wenzhou Medical College,Wenzhou, China[8]Joint Shantou International Eye Center, Shantou University& the Chinese University of Hong Kong, Shantou, China[9]Peking UniversityThird Hospital, Peking University Eye Center, Beijing, China[10]Eye Centre ofTianjin Medical University, Tianjin, China[11]Eye Institute and Xiamen EyeCenter of Xiamen University, Xiamen, China[12]Allergan InformationConsulting (Shanghai) Co.,Ltd.,Shanghai, China
Background: To report the clinical outcomes in Chinese patients with primary open-angle glaucoma and ocular hypertension treated with bimatoprost 0.03% therapy. Methods: Two hundred sixty-three Chinese patients with primary open-angle glaucoma and ocular hypertension who needed initial or additional intraocular pressure (IOP) lowering were recruited in this prospective, open-label, multicenter clinical study and were treated with bimatoprost 0.03%. Patients received bimatoprost 0.03% as initial, replacement or adjunctive IOP-lowering therapy, and follow-up visits were performed at week 1, and month 1 and 3 of the bimatoprost treatment. The efficacy outcome measure was the post-treatment IOP level. The safety outcome measures included the rate of medication-related symptoms, physical signs, reported adverse events, and the level of conjunctival hyperemia. Results: Among 240 patients who could be categorized by pre-existing therapies and the bimatoprost therapy regimen in the study, IOP values observed in all medication conditions showed significant IOP reduction at all study visits compared with baseline. At 3 months, 8.0 +/- 3.7 mmHg (32.0%) reduction in IOP was observed in treatment-naive patients after bimatoprost monotherapy; in the patients previously on various therapy regimens, 1.9 +/- 2.8 mmHg (9.5%) to 6.4 +/- 6.1 mmHg (24.8%) additional IOP lowering was achieved after switching to bimatoprost monotherapy or bimatoprost combination therapy. The most common adverse event was conjunctival hyperemia, mainly of trace and mild intensity. Conclusions: Our results show that bimatoprost 0.03% was effective in lowering IOP with favorable safety in Chinese primary open-angle glaucoma and ocular hypertension patients.
基金：
Allergan Information Consulting (Shanghai) Co., Ltd.
第一作者机构：[1]Eye & ENT Hospital, Shanghai Medical College, Fudan University, FenyangRoad 83, Shanghai, Xuhui District 200031, China
通讯作者：
推荐引用方式(GB/T 7714)：
Kaidi Wang,Li Xu,Zhilan Yuan,et al.Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China[J].BMC OPHTHALMOLOGY.2014,14:doi:10.1186/1471-2415-14-21.
APA：
Kaidi Wang,Li Xu,Zhilan Yuan,Ke Yao,Junmei Zhao...&Xinghuai Sun.(2014).Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.BMC OPHTHALMOLOGY,14,
MLA：
Kaidi Wang,et al."Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China".BMC OPHTHALMOLOGY 14.(2014)
